Comment
doi: 10.1016/j.jcmg.2020.07.025.
Epub 2020 Sep 11.
Dapagliflozin Improves Left Ventricular Myocardial Longitudinal Function in Patients With Type 2 Diabetes
- PMID: 32928703
- DOI: 10.1016/j.jcmg.2020.07.025
Item in Clipboard
Comment
Dapagliflozin Improves Left Ventricular Myocardial Longitudinal Function in Patients With Type 2 Diabetes
JACC Cardiovasc Imaging.
2021 Feb.
Free article
No abstract available
Comment on
-
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.Eur Heart J. 2020 Sep 21;41(36):3421-3432. doi: 10.1093/eurheartj/ehaa419. Eur Heart J. 2020. PMID: 32578850 Free PMC article. Clinical Trial.
Similar articles
-
Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.Cardiovasc Diabetol. 2020 Jan 7;19(1):6. doi: 10.1186/s12933-019-0985-z. Cardiovasc Diabetol. 2020. PMID: 31910853 Free PMC article.
-
Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.Diabetes. 2021 Jan;70(1):262-267. doi: 10.2337/db20-0840. Epub 2020 Oct 28. Diabetes. 2021. PMID: 33115828
-
Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.Cardiovasc Diabetol. 2018 Oct 8;17(1):132. doi: 10.1186/s12933-018-0775-z. Cardiovasc Diabetol. 2018. PMID: 30296931 Free PMC article. Clinical Trial.
-
Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.J Pharm Pract. 2016 Apr;29(2):165-71. doi: 10.1177/0897190014566308. Epub 2015 Jan 21. J Pharm Pract. 2016. PMID: 25609661 Review.
-
Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.Expert Rev Clin Pharmacol. 2011 Nov;4(6):669-83. doi: 10.1586/ecp.11.54. Expert Rev Clin Pharmacol. 2011. PMID: 22111852 Review.
Cited by
-
Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.Front Cardiovasc Med. 2024 May 16;11:1289663. doi: 10.3389/fcvm.2024.1289663. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38818214 Free PMC article.
-
Dapagliflozin, inflammation and left ventricular remodelling in patients with type 2 diabetes and left ventricular hypertrophy.BMC Cardiovasc Disord. 2024 Jul 12;24(1):356. doi: 10.1186/s12872-024-04022-7. BMC Cardiovasc Disord. 2024. PMID: 38997620 Free PMC article. Clinical Trial.
-
Clinical implications of left atrial reverse remodelling after cardiac resynchronization therapy.Eur Heart J Cardiovasc Imaging. 2022 Jun 1;23(6):730-740. doi: 10.1093/ehjci/jeac042. Eur Heart J Cardiovasc Imaging. 2022. PMID: 35213709 Free PMC article.
-
Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention.Front Cardiovasc Med. 2021 Sep 29;8:746382. doi: 10.3389/fcvm.2021.746382. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34660744 Free PMC article. Review.
-
ELUCIDATE Trial: A Single-Center Randomized Controlled Study.J Am Heart Assoc. 2024 May 7;13(9):e033832. doi: 10.1161/JAHA.123.033832. Epub 2024 Apr 19. J Am Heart Assoc. 2024. PMID: 38639353 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
